MAGAZINE

International Journal of Retina and Vitreous

Single retinal image for diabetic retinopathy screening: performance of a handheld device with embedded artificial intelligence

AUTHORS & DATE

Fernando Marcondes Penha, Bruna Milene Priotto, Francini Hennig, Bernardo Przysiezny, Bruno Antunes Wiethorn, Julia Orsi, Isabelle Beatriz Freccia Nagel, Brenda Wiggers, Jose Augusto Stuchi, Diego Lencione, Paulo Victor de Souza Prado, Fernando Yamanaka, Fernando Lojudice and Fernando Korn Malerbi
10/07/2023

Abstract

Background

Diabetic retinopathy (DR) is a leading cause of blindness. Our objective was to evaluate the performance of an artificial intelligence (AI) system integrated into a handheld smartphone-based retinal camera for DR screening using a single retinal image per eye.

Methods

Images were obtained from individuals with diabetes during a mass screening program for DR in Blumenau, Southern Brazil, conducted by trained operators. Automatic analysis was conducted using an AI system (EyerMapsTM, Phelcom Technologies LLC, Boston, USA) with one macula-centered, 45-degree field of view retinal image per eye. The results were compared to the assessment by a retinal specialist, considered as the ground truth, using two images per eye. Patients with ungradable images were excluded from the analysis.

Results

A total of 686 individuals (average age 59.2±13.3 years, 56.7% women, diabetes duration 12.1±9.4 years) were included in the analysis. The rates of insulin use, daily glycemic monitoring, and systemic hypertension treatment were 68.4%, 70.2%, and 70.2%, respectively. Although 97.3% of patients were aware of the risk of blindness associated with diabetes, more than half of them underwent their first retinal examination during the event. The majority (82.5%) relied exclusively on the public health system. Approximately 43.4% of individuals were either illiterate or had not completed elementary school. DR classification based on the ground truth was as follows: absent or nonproliferative mild DR 86.9%, more than mild (mtm) DR 13.1%. The AI system achieved sensitivity, specificity, positive predictive value, and negative predictive value percentages (95% CI) for mtmDR as follows: 93.6% (87.8–97.2), 71.7% (67.8–75.4), 42.7% (39.3–46.2), and 98.0% (96.2–98.9), respectively. The area under the ROC curve was 86.4%.

Conclusion

The portable retinal camera combined with AI demonstrated high sensitivity for DR screening using only one image per eye, offering a simpler protocol compared to the traditional approach of two images per eye. Simplifying the DR screening process could enhance adherence rates and overall program coverage.

Icon Button Request A QuoteRequest a Quote

Fechar

Ico Back

Later

Request a quote

Fill out the form below and we will contact you shortly.

    Ico Form Success

    Request a Quote

    Our team will contact you shortly.

    Close

    …complete suas informações

      By clicking the Complete button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
      Ico Back

      Depois

      Ico Form Success

      Obrigado por completar suas informações

      FECHAR

      Ico Back

      Depois

      Solicite e comece SEU TEST DRIVE

      Por favor, preencha o formulário abaixo que entraremos em contato.

        x

        Solicitar Orçamento

        Ao clicar em Solicitar, concordo com a Política de Privacidade e os Termos de Uso, permito que a Phelcom me contate e reconheço que o Eyer é um dispositivo médico (Anvisa classe II) exigindo a supervisão de um profissional com CRM para uso e interpretação das imagens.
        Ico Form Success

        Obrigado!

        Nosso time comercial logo entrará em contato para finalizar o processo.

        FECHAR

        Ico Back

        Later

        Request more information

        Please fill out the form below and we will contact you.

          x

          Request EyerMaps

          By clicking the Request button I allow Phelcom to contact me regarding the above request and I declare that I have read and accept the terms of Privacy Policy and Terms of Use.
          Ico Form Success

          Thank you!

          Our commercial team will contact you shortly to finalize the process.Our commercial team will contact you shortly to finalize the process.
          CLOSE